Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered...

Quell Therapeutics Highlights Clinical Potential of QEL-001 and its Multi-Modular Treg Cell Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Data demonstrating Quell’s ability to engineer Tregs to enhance their specific targeting and durability while maintaining their suppressive function and phenotypic stability to be presented in Oral...

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as...